Related Experiment Video
Updated: Jul 15, 2026
11:04
An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model
Published on: January 13, 2023
Photodynamic therapy for cutaneous verrucous carcinoma
Arjen F Nikkels1, Laurence Thirion, Pascale Quatresooz
1Department of Dermatopathology, University Hospital of Liège, Belgium. af.nikkels@chu.ulg.ac.be
Journal of the American Academy of Dermatology
|April 17, 2007
Summary
Methyl-aminolevulinate-photodynamic therapy (MAL-PDT) offers a new treatment for cutaneous verrucous carcinoma, a rare skin cancer. A successful case study shows its potential as a convenient therapeutic option.
Area of Science:
- Dermatology
- Oncology
- Photomedicine
Background:
- Cutaneous verrucous carcinoma is a rare, low-grade squamous cell carcinoma with indolent progression.
- Photodynamic therapy (PDT) utilizes photosensitizers and light to induce cancer cell death.
- Established treatments for verrucous carcinoma can be invasive.
Observation:
- An 82-year-old male presented with a large, long-standing verrucous carcinoma on his leg.
- The patient underwent 6 weekly sessions of MAL-PDT.
- Treatment involved methyl-aminolevulinate as the photosensitizer and 634-nm wavelength irradiation.
Findings:
- The methyl-aminolevulinate-photodynamic therapy (MAL-PDT) resulted in successful treatment of the cutaneous verrucous carcinoma.
- This represents the first reported use of MAL-PDT for this specific condition.
- The treatment regimen was well-tolerated and effective.
Implications:
- MAL-PDT may serve as a convenient and effective therapeutic alternative for cutaneous verrucous carcinoma.
- This approach could be particularly beneficial for patients seeking less invasive treatment options.
- Further research is warranted to establish the long-term efficacy and safety of MAL-PDT in managing verrucous carcinoma.
